Samsung Biologics is set to complete its global sales network across the three major biopharmaceutical markets – the U.S., Europe, and Japan – with the establishment of a new sales office in Europe. The company is ramping up its three-pillar growth strategy, focusing on expanding production capacity, diversifying its portfolio, and extending its global network to boost its competitive edge in securing contracts.
During a media briefing at the Bio International Convention 2026 in San Diego on Tuesday, John Lim, Chief Executive Officer (CEO) of Samsung Biologics, announced plans to open a European sales office in Amsterdam in the third quarter of 2026. He emphasized that this strategic location in the heart of Europe would serve as an optimal sales hub, enhancing accessibility and customer service efficiency.
Samsung Biologics has already established sales offices in New Jersey in 2023 and Tokyo in 2025. With the addition of the Netherlands office, the company will have a comprehensive sales infrastructure covering the key markets of the U.S., Europe, Japan, and the Asia-Pacific region – crucial areas for global biopharmaceutical demand.
According to market research firm Frost & Sullivan, these three major markets – the U.S., Europe, and Asia-Pacific – account for about 90% of the total biopharmaceutical market.
Leveraging its new European base, Samsung Biologics aims to accelerate its transformation from a production-focused Contract Development and Manufacturing Organization (CDMO) to a globally integrated sales and development network company. The strategy involves strengthening connections among dispersed customer touchpoints to expedite contract negotiations with major global pharmaceutical companies and enhance participation from the early stages of projects.
The company is also aggressively pursuing its production capacity expansion strategy. In March, it completed the acquisition of its Rockville facility in the U.S., boosting its total global production capacity to 845,000 liters. The Rockville plant has begun stable operations based on existing product manufacturing, with revenue recognition expected to start in the second quarter and ramp up significantly in the third quarter of this year.
Furthermore, Samsung Biologics plans to decide on the construction of its sixth facility within the year and continue expanding its second biocampus, aiming to increase total production capacity to 1,385,000 liters by 2032. Simultaneously, the company is initiating the development of a third biocampus to enhance its capabilities in next-generation modalities.
Alongside capacity expansion, Samsung Biologics is accelerating its portfolio diversification. The company is enhancing its CDMO competitiveness through its dedicated production facility for antibody-drug conjugates (ADCs), which has already entered commercial production. It’s also establishing a production line for ADC drug products (DP), targeting completion in the first quarter of 2027.
Rockville Facility Opens Doors For Strategic M&A Possibilities
Through these initiatives, Samsung Biologics aims to secure an end-to-end service system that connects everything from active pharmaceutical ingredients (DS) to finished products.
The company is also expanding into the contract research organization (CRO) sector with its Samsung Organoid service, strengthening its ability to engage clients from the earliest stages. It’s also exploring peptides and adeno-associated viruses (AAV) as potential long-term growth pillars in cell and gene therapies (CGT).
The global hub strategy is being pursued in parallel. While expanding production and sales synergies based on the Rockville facility, the company is open to additional strategic mergers and acquisitions (M&A). This approach aims to diversify its role within the global supply chain, going beyond mere production facility expansion.
CEO Lim stated that it will aggressively expand investments in next-generation biotechnologies and continuously broaden our global network and business opportunities through collaboration with invested companies.
He added that it will strengthen our competitiveness in customer relations, operations, quality, and talent based on the four core values (4E), and enhance the execution capabilities through the 3S strategy of simplification, standardization, and scalability, solidifying the position as a top-tier global CDMO.
Meanwhile, Samsung Biologics is actively investing in the biotech ecosystem. Through its Life Science Fund (LS Fund), it continues to invest in biotech firms, expanding its foundation for technological and business collaboration.
Following its first fund (170 billion KRW (about 109.9 million USD)) and second fund (72 billion KRW (about 46.5 million USD)), it recently established a third fund worth 200 billion KRW (about 129.3 million USD).
Samsung Biologics has set its annual revenue growth target for this year at 15-20% compared to the previous year. The company aims to maintain its long-term growth momentum based on its three strategic pillars: expanding production capacity, global hub expansion, and portfolio diversification.
